Drug Search Results
More Filters [+]

HSP-130

Alternative Names: hsp-130, hsp130, hsp 130, nyvepria
Latest Update: 2024-09-23
Latest Update Note: Clinical Trial Update

Product Description

ÊA long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04) (Sourced from: https://thesaurus.cancer.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.03e&code=C1854&ns=ncit&type=all&key=null&b=1&n=0&vse=null)

Mechanisms of Action: G-CSF Agonist

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HSP-130

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Choriocarcinoma|Endodermal Sinus Tumor|Embryonal Carcinoma|Teratoma|Germinoma|Breast Cancer|Mixed Tumor, Malignant|Febrile Neutropenia

Phase 1: Neutropenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACNS2021

P2

Recruiting

Endodermal Sinus Tumor|Teratoma|Germinoma|Choriocarcinoma|Embryonal Carcinoma|Mixed Tumor, Malignant

2029-12-21

2015-002057-35

P2

Completed

Febrile Neutropenia

2017-10-05

ZIN-130-1504

P2

Completed

Breast Cancer

2017-10-01

ZIN-130-1505

P1

Completed

Neutropenia

2016-06-01

Recent News Events